Conjugated linoleic acid attenuates 2, 4-dinitrofluorobenzene induced atopic dermatitis in mice through dual inhibition of COX-2/5-LOX and TLR4/NF-κB signaling

Abstract Conjugated linoleic acid (CLA), commonly found in beef, lamb and dairy products has been reported to exhibit anti-inflammatory and anti-pruritus effects and inhibit the release of chemical mediators such as histamine and eicosanoid in laboratory rodents. The chief objective of the study is to assess the efficacy of CLA on atopic dermatitis (AD) in mice and to explore possible mechanisms with CLA treatments. To develop a new therapy for AD, the anti-AD potential of CLA was investigated by inducing AD-like skin lesions in mice using 2, 4-dinitrofluorobenzene (DNFB). We evaluated dermatitis severity, histopathological changes, serum levels of T helper (Th) cytokines (interferon (IFN)-γ, interleukin (IL)-4), changes in protein expression by western blotting and immunohistochemistry staining for cyclooxygenase-2 (COX-2), 5-lipoxygenase (5-LOX), toll like receptor 4 (TLR-4), myeloid differentiation factor 88 (MyD88), nuclear factor-κB (NF-κB), tumor necrosis factor α (TNF-α), and production of the pro-inflammatory lipid mediators, such as prostaglandin E2 (PGE2) and leukotriene B4 (LTB4) in the skin lesions. Treatment with CLA ameliorated the development of AD-like clinical symptoms and effectively inhibited epidermal hyperplasia, infiltration of mast cells and CD4+T cells in the AD mouse skin.Total serum IgE levels and the expression levels of Th1,Th2 cytokines and lipid mediators in dorsal skin were dramatically suppressed by CLA. Furthermore, CLA down-regulated the expressions of COX-2, 5-LOX, TLR4, MyD88, NF-κB and TNF-α. Taken together, our findings demonstrate the potential usefulness of CLA as an anti-inflammatory dietary supplement or drug for the prevention and management of AD skin diseases by modulating the COX-2/5-LOX and TLR4/MyD88/NF-κB signaling pathways.